rdf:type |
|
lifeskim:mentions |
|
pubmed:dateCreated |
2005-1-17
|
pubmed:abstractText |
Peptide receptor scintigraphy in combination with anatomic imaging methods such as CT can be regarded as molecular imaging. It offers insight into the variability of somatostatin receptor expression in neuroendocrine tumor lesions within a patient. The somatostatin receptor status of all tumors in a patient is an important issue, because receptor-negative lesions may be poorly differentiated and characterized by aggressive growth and poor prognosis, with consequences for the choice of therapy.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0161-5505
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
46 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
76S-82S
|
pubmed:meshHeading |
pubmed-meshheading:15653655-Aged,
pubmed-meshheading:15653655-Gastrointestinal Neoplasms,
pubmed-meshheading:15653655-Humans,
pubmed-meshheading:15653655-Male,
pubmed-meshheading:15653655-Middle Aged,
pubmed-meshheading:15653655-Molecular Biology,
pubmed-meshheading:15653655-Neuroendocrine Tumors,
pubmed-meshheading:15653655-Pancreatic Neoplasms,
pubmed-meshheading:15653655-Peptides,
pubmed-meshheading:15653655-Physician's Practice Patterns,
pubmed-meshheading:15653655-Prognosis,
pubmed-meshheading:15653655-Radioisotopes,
pubmed-meshheading:15653655-Radionuclide Imaging,
pubmed-meshheading:15653655-Radiopharmaceuticals,
pubmed-meshheading:15653655-Somatostatin,
pubmed-meshheading:15653655-Treatment Outcome
|
pubmed:year |
2005
|
pubmed:articleTitle |
Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.
|
pubmed:affiliation |
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. E.P.Krenning@erasmusmc.nl
|
pubmed:publicationType |
Journal Article,
Case Reports
|